OR-UALINK
30.5.2024 14:01:28 CEST | Business Wire | Press release
AMD, Broadcom, Cisco, Google, Hewlett Packard Enterprise (HPE), Intel, Meta and Microsoft today announced they have aligned to develop a new industry standard dedicated to advancing high-speed and low latency communication for scale-up AI systems linking in Data Centers.
Called the Ultra Accelerator Link (UALink), this initial group will define and establish an open industry standard that will enable AI accelerators to communicate more effectively. By creating an interconnect based upon open standards, UALink will enable system OEMs, IT professionals and system integrators to create a pathway for easier integration, greater flexibility and scalability of their AI-connected data centers.
The Promoter Group companies bring extensive experience creating large-scale AI and HPC solutions based on open standards, efficiency and robust ecosystem support.
Driving Scale-Up for AI Workloads
As the demand for AI compute grows, it is critical to have a robust, low-latency and efficient scale-up network that can easily add computing resources to a single instance. Creating an open, industry standard specification for scale-up capabilities will help to establish an open and high-performance environment for AI workloads, providing the highest performance possible.
This is where UALink and an industry specification becomes critical to standardize the interface for AI and Machine Learning, HPC, and Cloud applications for the next generation of AI data centers and implementations. The group will develop a specification to define a high-speed, low-latency interconnect for scale-up communications between accelerators and switches in AI computing pods.
The 1.0 specification will enable the connection of up to 1,024 accelerators within an AI computing pod and allow for direct loads and stores between the memory attached to accelerators, such as GPUs, in the pod. The UALink Promoter Group has formed the UALink Consortium and expects it to be incorporated in Q3 of 2024. The 1.0 specification is expected to be available in Q3 of 2024 and made available to companies that join the Ultra Accelerator Link (UALink) Consortium.
About Ultra Accelerator Link
Ultra Accelerator Link (UALink) is a high-speed accelerator interconnect technology that advances next-generation AI/ML cluster performance. AMD, Broadcom, Cisco, Google, HPE, Intel, Meta and Microsoft are forming an open industry standard body to develop technical specifications that facilitate breakthrough performance for emerging usage models while supporting an open ecosystem for data center accelerators.
Supporting Quotes
“The work being done by the companies in UALink to create an open, high performance and scalable accelerator fabric is critical for the future of AI. Together, we bring extensive experience in creating large scale AI and high-performance computing solutions that are based on open-standards, efficiency and robust ecosystem support. AMD is committed to contributing our expertise, technologies and capabilities to the group as well as other open industry efforts to advance all aspects of AI technology and solidify an open AI ecosystem.” – Forrest Norrod, executive vice president and general manager, Data Center Solutions Group, AMD
"Broadcom is proud to be one of the founding members of the UALink Consortium, building upon our long-term commitment to increase large-scale AI technology implementation into data centers. It is critical to support an open ecosystem collaboration to enable scale-up networks with a variety of high-speed and low-latency solutions.” – Jas Tremblay, vice president and general manager of the Data Center Solutions Group, Broadcom
“Ultra-high performance interconnects are becoming increasingly important as AI workloads continue to grow in size and scope. Together, we are committed to developing the UALink which will be a scalable and open solution available to help overcome some of the challenges with building AI supercomputers.” – Martin Lund, Executive Vice President, Common Hardware Group, Cisco
“Open standards are important to HPE as we innovate in supercomputing and increase access to systems. As a founding member of the UALink industry consortium, we look forward to contributing our expertise in high performance networking and systems, and collaborating to develop a new open standard for accelerator interconnects for the next generation of supercomputing.” – Trish Damkroger, senior vice president and general manager, HPC & AI Infrastructure Solutions, HPE
“UALink is an important milestone for the advancement of Artificial Intelligence computing. Intel is proud to co-lead this new technology and bring our expertise in creating an open, dynamic AI ecosystem. As a founding member of this new consortium, we look forward to a new wave of industry innovation and customer value delivered though the UALink standard. This initiative extends Intel’s commitment to AI connectivity innovation that includes leadership roles in the Ultra Ethernet Consortium and other standards bodies.” – Sachin Katti, SVP & GM, Network and Edge Group, Intel Corporation
“In a very short period of time, the technology industry has embraced challenges that AI and HPC have uncovered. Interconnecting accelerators like GPUs requires a holistic perspective when seeking to improve efficiencies and performance. At UEC, we believe that UALink’s scale-up approach to solving pod cluster issues complements our own scale-out protocol, and we are looking forward to collaborating together on creating an open, ecosystem-friendly, industry-wide solution that addresses both kinds of needs in the future.” – J Metz, Ph.D., Chair, Ultra Ethernet Consortium
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530653602/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
